In my very first post on this blog, I proudly pronounced that this would not become one of those places where quack-busters have field-day. However, I am aware that, so far, I have not posted many complimentary things about alternative medicine. My ‘excuse’ might be that there are virtually millions of sites where this area is uncritically promoted and very few where an insider dares to express a critical view. In the interest of balance, I thus focus of critical assessments.
Yet I intend, of course, report positive news when I think it is relevant and sound. So, today I shall discuss a new trial which is impressively sound and generates some positive results:
French rheumatologists conducted a prospective, randomised, double blind, parallel group, placebo controlled trial of avocado-soybean-unsaponifiables (ASU). This dietary supplement has complex pharmacological activities and has been used since years for osteoarthritis (OA) and other conditions. The clinical evidence has, so far, been encouraging, albeit not entirely convincing. My own review arrived at the conclusion that “the majority of rigorous trial data available to date suggest that ASU is effective for the symptomatic treatment of OA and more research seems warranted. However, the only real long-term trial yielded a largely negative result”.
For the new trial, patients with symptomatic hip OA and a minimum joint space width (JSW) of the target hip between 1 and 4 mm were randomly assigned to three years of 300 mg/day ASU-E or placebo. The primary outcome was JSW change at year 3, measured radiographically at the narrowest point.
A total of 399 patients were randomised. Their mean baseline JSW was 2.8 mm. There was no significant difference on mean JSW loss, but there was 20% less progressors in the ASU than in the placebo group (40% vs 50%, respectively). No difference was observed in terms of clinical outcomes. Safety was excellent.
The authors concluded that 3 year treatment with ASU reduces the speed of JSW narrowing, indicating a potential structure modifying effect in hip OA. They cautioned that their results require independent confirmation and that the clinical relevance of their findings require further assessment.
I like this study, and here are just a few reasons why:
It reports a massive research effort; I think anyone who has ever attempted a 3-year RCT might agree with this view.
It is rigorous; all the major sources of bias are excluded as far as humanly possible.
It is well-reported; all the essential details are there and anyone who has the skills and funds would be able to attempt an independent replication.
The authors are cautious in their interpretation of the results.
The trial tackles an important clinical problem; OA is common and any treatment that helps without causing significant harm would be more than welcome.
It yielded findings which are positive or at least promising; contrary to what some people seem to believe, I do like good news as much as anyone else.
I WISH THERE WERE MORE ALT MED STUDIES/RESEARCHERS OF THIS CALIBER!